Category

Archives

c-Met

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer

1 views | Jun 15 2021

K Kato et al. suggested that NIVO treatment was a more favorable option for patients with slow-growing tumors, and NIVO and IRI were similarly recommended for patients with rapid-growing tumors in refractory AGC. TGR and NL emergence during preceding treatment might be helpful for drug selection and warrant further investigation. [Read the Full Post]

Exosomes derived from miR-16-5p-overexpressing keratinocytes attenuates bleomycin-induced skin fibrosis

5 views | May 24 2021

Yunyao Bo et al. thought that the localized delivery of miR-16-5p by keratinocytes-derived exosomes might have potential for efficient clinical treatment of skin fibrosis. [Read the Full Post]

Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition

10 views | Apr 13 2021

Narges K Gortany et al.indicated that foretinib might have the therapeutic potential against human GBM which deserve further investigation. [Read the Full Post]

Depletion of insulin-like growth factor 1 receptor increases radiosensitivity in colorectal cancer

11 views | Mar 21 2021

Yi Li et al. supported the notion that the radiosensitivity of radiation-resistant colorectal cancer cells could be enhanced by directly targeting IGF1R expression or activity. [Read the Full Post]

Differential functional roles of fibroblasts and pericytes in the formation of tissue-engineered microvascular networks in vitro

18 views | Jan 27 2021

Natalia Kosyakova et al. described the differential effects that two widely used stromal cell populations, fibroblasts (FBs) and pericytes (PCs), had on μVN formation. [Read the Full Post]

Suppression of MET signaling mediated by pitavastatin and capmatinib inhibits oral and esophageal cancer cell growth

22 views | Jan 26 2021

Bo Xu et al. suggested that the combination of pitavastatin with capmatinib was a useful therapeutic strategy in OSCC and ESCC. [Read the Full Post]

Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer

20 views | Jan 19 2021

Yi-Zhi Liu et al. found that RON, PD-L1, and their crosstalk were significant in predicting the prognostic value of CRC. [Read the Full Post]

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

27 views | Nov 19 2020

Alwin G Schuller et al. provided the first report testing therapeutics in preclinical in vivo models of PRCC and supported the clinical development of AZD6094 in the indication. [Read the Full Post]

Discovery of Novel Dual c-Met/HDAC Inhibitors as a Promising Strategy for Cancer Therapy

133 views | Jul 07 2020

Hao Hu et al. provided an efficient strategy for discovery of multitarget antitumor drugs. [Read the Full Post]

STMN1 Upregulation Mediates Hepatocellular Carcinoma and Hepatic Stellate Cell Crosstalk to Aggravate Cancer by Triggering the MET Pathway

145 views | Jun 15 2020

Rui Zhang et al. suggested that STMN1 may be used as a potential marker to identify patients who may benefit from MET inhibitor treatment. [Read the Full Post]